Neurology
AbbVie’s Aquipta receives MHRA marketing authorisation
September 5, 2023Sales and Marketing AbbVie, Aquipta, MHRA, Neurology, atogepant, migraines
AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), …
FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS
August 25, 2023Medical Communications FDA, MS, Neurology, Sandoz
Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko (natalizumab-sztn), developed by …
Biogen to acquire Reata Pharmaceuticals
July 31, 2023Business Services Biogen, Neurology, Reata Pharmaceuticals, acquisition
Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for …
BioIVT acquires PrecisionMed for neurology and oncology research
July 21, 2023Sales and Marketing Neurology, Oncology, neurology, oncology
BioIVT has announced that it has acquired PrecisionMed, a leading supplier of high-quality human biological material for genetics, drug discovery …
Eli Lilly shares results from phase 3 trial of donanemab for Alzheimer’s treatment
July 18, 2023Research and Development Alzheimer's, Eli Lilly, Neurology, clinical trial, donanemab
Eli Lilly has presented full results from the phase 3 TRAILBLAZER-ALZ 2 study which assessed donanemab for the treatment of …
Alnylam shares positive results from phase 1 trial
July 17, 2023Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …
Genentech shares results from phase 3 trial for MS treatment
July 13, 2023Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial
Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …
FDA grants Alzheimer’s disease drug Leqembi full approval
July 7, 2023Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology
Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food and Drug Administration (FDA) has …
Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy
July 3, 2023Research and Development HTL'149, Neurology, Sosei Heptares, clinical trial, schizophrenia
Sosei Heptares has announced that it has dosed its first patient in its phase 1 trial evaluating HTL0048149 (HTL’149), a …
Cartesian Therapeutics announces successful trial of RNA cell therapy in autoimmunity
June 23, 2023Research and Development Cartesian Therapeutics, Neurology, RNA, autoimmune, neurology
Clinical stage biotechnology company, Cartesian Therapeutics, has announced results from its clinical trial using RNA CAR T (rCAR T) therapy …
PharmaTher and Vitruvias sign collaboration agreement to commercialise ketamine-based treatment in the US
June 21, 2023Medical Communications Ketamine, Neurology, PharmaTher, Vitruvias, commercialisation
Specialty pharmaceutical companies, Canadian PharmaTher and US-based Vitruvias, have entered into a commercialisation partnership to bring Ketarx products to the …
Axol Bioscience and StrataStem collaborate to deliver ‘clinical trial in a dish’ for Alzheimer’s disease
June 7, 2023Research and Development Alzheimer's, Axol Bioscience, Neurology, StrataStem
Pluripotent stem cell technology provider Axol Bioscience has signed an exclusive agreement with UK-based StrataStem to access and commercialise its …
AstraZeneca’s phase 4 trial stopped early after reaching pre-specified criteria
June 5, 2023Research and Development ANNEXA-I, Andexxa, AstraZeneca, Neurology, clinical trial
AstraZeneca has announced that its post-marketing phase 4 ANNEXA-I trial has been stopped early after reaching its pre-specified stopping criteria. …
NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks
June 2, 2023Medical Communications NHS, NICE, Neurology, Pfizer, migraine
The National Institute for Health and Care Excellence (NICE) has announced that it has recommended an oral treatment for the …
Sanofi announce positive phase 2 data for MS drug frexalimab
June 1, 2023Research and Development Neurology, Sanofi, clinical trial, frexalimab, multiple sclerosis
French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 clinical study into its relapsing …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
